Ami Vijay Desai, MD
All 3 patients with targeted gene fusions responded to the multikinase inhibitor entrectinib, according to a phase I study in children and young adults with advanced, previously treated central nervous system (CNS) tumors. Ami Vijay Desai, MD, presented these findings during the 2018 ASCO Annual Meeting.
“Entrectinib continues to be investigated in expansion cohorts of patients with extracranial solid tumors or primary CNS tumors harboring somatic gene fusions, as well as patients with neuroblastoma,” noted Desai during her presentation.
Desai AV, Brodeur GM, Foster J, et al. Phase I study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. J Clin Oncol. 2018;36(suppl;abstr 10536).
... to read the full story